Advanced search
Publication Cover
Journal of Hepatocellular Carcinoma Volume 3, 2016 - Issue
Submit an article Journal homepage
72
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma

Armeen Mahvash1 Department of Interventional RadiologyCorrespondence[email protected]
,
Ravi Murthy1 Department of Interventional Radiology
,
Bruno C Odisio1 Department of Interventional Radiology
,
Kanwal Pratap Raghav2 Department of Gastrointestinal Medical Oncology
,
Lauren Girard2 Department of Gastrointestinal Medical Oncology
,
Sheree Cheung1 Department of Interventional Radiology
,
Van Nguyen3 Department of Pharmacy
,
Joe Ensor4 Department of Statistics, The University of Texas MD Anderson Cancer Center, Houston, TX
,
Sameer Gadani5 Department of Radiology, Saint Louis University Hospital, St Louis, MO
,
Khaled M Elsayes6 Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
,
Reham Abdel-Wahab1 Department of Interventional Radiology;7 Department of Clinical Oncology, Assiut University Hospital, Assiut, Egypt
,
Manal Hassan1 Department of Interventional Radiology
,
Ahmed S Shalaby1 Department of Interventional Radiology
,
James C Yao1 Department of Interventional Radiology
,
Michael J Wallace1 Department of Interventional Radiology
&
Ahmed O Kaseb2 Department of Gastrointestinal Medical OncologyCorrespondence[email protected]
 show all
Pages 1-7 | Published online: 05 Feb 2016

References

  • LlovetJMRicciSMazzaferroVSorafenib in advanced hepatocellular carcinomaN Engl J Med2008359437839018650514
  • LlovetJMBustamanteJCastellsANatural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trialsHepatology199929162679862851
  • ChengALKangYKChenZEfficacy and safety of sorafenib in patients in the Asia–Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialLancet Oncol2009101253419095497
  • HallEJRadiobiology for the RadiologistPhiladelphia, PALippincott Williams & Wilkins2000
  • BruixJShermanMManagement of hepatocellular carcinoma: an updateHepatology20115331020102221374666
  • NarazakiMTosatoGLigand-induced internalization selects use of common receptor neuropilin-1 by VEGF165 and semaphorin3ABlood2006107103892390116424390
  • SangroBCarpaneseLCianniRSurvival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluationHepatology201154386887821618574
  • KennedyASNuttingCColdwellDGaiserJDrachenbergCPathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole liversInt J Radiat Oncol Biol Phys20046051552156315590187
  • SangroBGil-AlzugarayBRodriguezJLiver disease induced by radioembolization of liver tumors: description and possible risk factorsCancer200811271538154618260156
  • SaccoRAntonucciMBargelliniIMarcegliaSMismasVCabibboGTransarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?Future Oncol20151113
  • YaoXYanDLiuDZengHLiHEfficacy and adverse events of transcatheter arterial chemoembolization in combination with sorafenib in the treatment of unresectable hepatocellular carcinomaMol Clin Oncol20153492993526171209
  • ChenSWLinLCKuoYCLiangJAKuoCCChiouJFPhase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinomaInt J Radiat Oncol Biol Phys20148851041104724661657
  • KulikLVoucheMKoppeSProspective randomized pilot study of Y90+/− sorafenib as bridge to transplantation in hepatocellular carcinomaJ Hepatol201461230931724681342
  • VoucheMKulikLAtassiRRadiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: imaging analysis from a prospective randomized trial of Y90 +/− sorafenibHepatology20135851655166623703789
  • MaBBBristowRGKimJSiuLLCombined-modality treatment of solid tumors using radiotherapy and molecular targeted agentsJ Clin Oncol200321142760277612860956
  • Abou-AlfaGKSchwartzLRicciSPhase II study of sorafenib in patients with advanced hepatocellular carcinomaJ Clin Oncol200624264293430016908937
  • LiuLCaoYChenCSorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5Cancer Res20066624118511185817178882
  • LlovetJMBurroughsABruixJHepatocellular carcinomaLancet200336293991907191714667750
  • LiQHuYXiMHeLZhaoLLiuMSorafenib modulates the radio sensitivity of hepatocellular carcinoma cells in vitro in a schedule-dependent mannerBMC Cancer20121248523088517

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.